From new industry M&As to insights on how to recruit Gen Z talent, there’s plenty to discover in our latest pharma news round ...

Learn about June 2025’s top biotech deals, featuring major collaborations in small molecules, protein therapeutics, and ...

(STAT News) How a dinner in Paris revived talks for Sanofi’s $9.5 billion deal for Blueprint Medicines. For Blueprint Medicines, a monumental meal in the City of Bridges helped bring back to life ...

Kymera Therapeutics is celebrating the signing of two partnerships, with Gilead Sciences taking an option on one molecular glue programme, as Sanofi buys into another.

Halper Sadeh LLC, an investor rights law firm, is investigating the following companies for potential violations ...

BIO was as busy as ever in Boston this year. With more to come soon, here are a few initial thoughts on three events I ...

Eli Lilly has struck a deal to buy Crispr gene-editing start-up Verve Therapeutics for up to $1.3bn, the latest acquisition by the world’s most valuable drugmaker as it seeks to boost its pipeline of ...

However, amid the broader macro uncertainty, the drug and biotech sector seems to have recovered in the past month, backed by positive pipeline and regulatory developments. Innovation is at its peak ...

In conclusion, Blueprint Medicines stands at a pivotal juncture with its recent acquisition by Sanofi and the continued success of Ayvakit. The stock has demonstrated strong momentum, with a 37.31% ...

Blueprint Medicines (NASDAQ: BPMC) Corporation, a commercial-stage biotechnology company with a market capitalization of $8.27 billion, has been making significant strides in the pharmaceutical ...

Detailed price information for Blueprint Medicines Corp (BPMC-Q) from The Globe and Mail including charting and trades.